Hypercholesterolaemia and its management

@article{Bhatnagar2008HypercholesterolaemiaAI,
  title={Hypercholesterolaemia and its management},
  author={D. Bhatnagar and H. Soran and P. Durrington},
  journal={BMJ : British Medical Journal},
  year={2008},
  volume={337}
}
Hypercholesterolaemia is one of the major causes of atherosclerosis. Although there are many causes, hypercholesterolaemia is the permissive factor that allows other risk factors to operate.1 The incidence of coronary heart disease is usually low where population plasma cholesterol concentrations are low.2 In Britain coronary heart disease is a major cause of mortality, and a recent Department of Health survey suggested that the average plasma cholesterol concentration in the United Kingdom was… Expand
INTRODUCTION TO HYPERLIPIDEMIA AND ITS TREATMENT: A REVIEW
TLDR
The global increase in the prevalence of hyperlipidemia is due to unhealthy eating habits, obesity and physical inactivity, and the emergencies, risk factors and remedies are described in the literature. Expand
Mortality for individuals with familial hypercholesterolemia(FH) in the period 1992-2010.
TLDR
At age 0-59, cancer and none-CVD death cause had lower total SMR among FH individuals, than the general population, and individuals with FH have higher prevalence of death by CVD, thanThe general population. Expand
AN HUGE UPDATED REVIEW ON DYSLIPIDEMIA ETIOLOGY WITH VARIOUS APPROACHES FOR ITS TREATMENT
TLDR
A complete overview on dyslipidemia, its impact on the progression of cardiovascular diseases, its various forms, pharmacological interventions involved in its treatment and most recent investigations which are fruitful in the understanding of the disease and helpful to take preventive measures for cardiovascular diseases are reviewed. Expand
Cascade screening for familial hypercholesterolaemia and its effectiveness in the prevention of vascular disease
TLDR
How cascade screening for familial hypercholesterolaemia will be implemented into primary and secondary care, its potential advantages and disadvantages, and how it will help to prevent myocardial infarctions in patients with FH are considered. Expand
High-density lipoprotein cholesterol raising: does it matter?
TLDR
There is evidence to support the view that HDL functionality and the mechanism by which a therapeutic agent raises HDL-C are more important than plasma cholesterol levels, rather than simply raising the cholesterol cargo. Expand
Molecular aspects of hypercholesterolemia treatment: current perspectives and hopes
TLDR
The molecular aspects of current and novel therapeutic approaches based on low-density lipoprotein cholesterol lowering strategies and the most common genes involved in hypercholesterolemia are LDLR, PCSK9 and ApoB are reviewed. Expand
A Review on Hyperlipidemic
INTRODUCTION Hyperlipidemia is a condition excess of fatty substances called lipids, largely cholesterol and triglycerides, in the blood. It is also called hyperlipoproteinemia because these fattyExpand
Severe hypercholesterolemia mediated by lipoprotein X in a patient with cholestasis.
TLDR
This case highlights the significance of LpX as a cause of severe hypercholesterolemia in a patient with cholestasis secondary to a granulomatous hepatitis attributed to tuberculosis. Expand
Hypercholesterolaemia – practical information for non-specialists
TLDR
A background into hypercholesterolaemia for non-specialists is provided and the merits of the different risk assessment tools available are considered. Expand
Polygenic Hyperlipidemias and Coronary Artery Disease Risk
TLDR
The CAD risk associated with a high polygenic load for lipid-increasing variants was proportional to their impact on lipid levels and partially overlapping with a CAD PRS, and the lipid PRSs point to known and directly modifiable risk factors providing additional guidance for clinical translation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 42 REFERENCES
Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.
TLDR
Blood cholesterol concentration was directly related to mortality from coronary heart disease even in those with what was, by Western standards, a "low" cholesterol concentration. Expand
The safety of statins in clinical practice
TLDR
For most people, statins are safe and well-tolerated, and their widespread use has the potential to have a major effect on the global burden of cardiovascular disease. Expand
Diagnosis and screening for familial hypercholesterolaemia: finding the patients, finding the genes
TLDR
Clinicians need to be made more aware of the clinical features of FH and how to diagnose it in order to increase the index of suspicion and instigate appropriate treatment early, with the aim of preventing premature coronary heart disease. Expand
Indications for cholesterol-lowering medication: comparison of risk-assessment methods
BACKGROUND Recommendations for the prescription of lipid-lowering drugs emphasise the importance of an assessment of absolute coronary heart disease (CHD) risk based on all risk factors, rather thanExpand
Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds.
  • S. Grundy
  • Medicine
  • Journal of the American College of Cardiology
  • 2006
TLDR
Primary treatment of the metabolic syndrome is lifestyle therapy--weight loss, increased physical activity, and anti-atherogenic diet, but as the condition progresses, drug therapies directed toward the individual risk factors might be required. Expand
Risk for myopathy with statin therapy in high-risk patients.
TLDR
Clinicians should be alert to the potential for drug-drug interactions to minimize the risk of myopathy during long-term statin therapy in patients at high risk for coronary heart disease. Expand
Outcome of case finding among relatives of patients with known heterozygous familial hypercholesterolaemia
TLDR
By performing cholesterol tests on 200 relatives, 121 new patients with familial hypercholesterolaemia were discovered, and only a few of these patients would have been detected had cholesterol testing been restricted to those with other risk factors for coronary heart disease. Expand
Coronary Artery Disease in 116 Kindred with Familial Type II Hyperlipoproteinemia
TLDR
This study, the largest of its kind, permitted more precise and extensive determination of the CAD risk accompanying severe hyperbetalipoproteinemia than has heretofore been possible. Expand
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
TLDR
Statins can lower LDL cholesterol concentration by an average of 1.8 mmol/l which reduces the risk of IHD events by about 60% and stroke by 17% and is corroborated by results from the nine cohort studies. Expand
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins
TLDR
Statin therapy can safely reduce the 5-year incidence of major coronary events, coronary revascularisation, and stroke by about one fifth per mmol/L reduction in LDL cholesterol, largely irrespective of the initial lipid profile or other presenting characteristics. Expand
...
1
2
3
4
5
...